Best CJC-1295/Ipamorelin Providers in 2026 — Ranked & Reviewed

CJC-1295 and ipamorelin target different steps of the growth-hormone release cascade and are commonly compounded together as a single stack — CJC-1295 extends the pituitary's GH pulse, ipamorelin selectively triggers it without meaningfully raising cortisol or prolactin. Both require a prescription and a compliant compounding pharmacy, which is where the current landscape gets complicated. See below for the current status.

New to CJC-1295 / Ipamorelin? Read our full CJC-1295 / Ipamorelin guide — evidence, dosing, safety and side effects.

WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. Learn more

By Eli Marsden · Founding Editor
Editorially reviewed & fact-checked against primary sources · How we verify contentLast reviewed

Why there’s no ranking here yet

CJC-1295 and ipamorelin's nominations for the FDA's Section 503A Bulk Drug Substances List were withdrawn, and neither compound is on that list today — so no 503A compounding pharmacy has a current lawful basis to sell them, regardless of what any individual provider's page claims. Unlike BPC-157, TB-500, and MOTS-c, these two were not part of the FDA advisory committee's July 2026 positive recommendation, so we don't have a clear approval timeline to point to. We'll rank providers here the moment we can confirm one is legally compliant.

We’d rather show nothing than list a provider who can’t legally sell this yet. We’re tracking the FDA’s decision and will rank compliant providers here the moment one exists.

How we rank & what counts as “legit”

Every provider in this ranking is scored against our published six-factor rubric[1] — value, effectiveness, user experience, trust & safety, accessibility, and support.

Brand-name Wegovy, Zepbound, Ozempic, and Mounjaro are separately FDA-approved under their own NDA numbers[4][5]. Published Phase 3 efficacy for semaglutide 2.4 mg (~14.9% mean weight loss over 68 weeks) comes from the STEP 1 trial[6], and for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) from SURMOUNT-1[7]; the SURMOUNT-5 head-to-head published in 2025 compared the two directly[8].

Insurance coverage for anti-obesity medications varies widely by state Medicaid program and commercial plan[9][10]. Compounded and brand-name GLP-1s are generally FSA/HSA eligible with a prescription under IRS Publication 502[11].

Always verify pricing and state availability on the provider's website before signing up.How our reviews work →

Frequently Asked Questions

Sources & methodology — as of August 2026
  1. 1.Weight Loss Rankings — GLP-1 Pricing Index 2026 (our independent dataset)— WeightLossRankings.org.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings